On October 21, 2025, results from Alector Therapeutics’ Phase 3 clinical trial for Latozinemab (AL001) were announced. This intervention, designed for people with FTD caused by variants in the GRN gene, did not have an impact on clinical symptoms nor on a number of other endpoints. We know many people have questions and concerns about these results, including what they mean for people with FTD-GRN as well as for other causes of FTD. Join AFTD’s Director of Scientific Initiatives, Dr. Penny Dacks; the Chair-Elect of AFTD’s Medical Advisory Committee, Professor at the University of Toronto, and cognitive behavioral neurologist at the UHN Memory Clinic, Dr. Carmela Tartaglia; and members of the community to discuss the trial results and address your questions.